#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=6 .
1-1	0-1	6	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=HIF and Vascular Diseases
2-1	4-7	HIF	event|abstract[3]	new|new[3]	coref|coref|coref|coref	4-5|8-1[54_3]|4-5|8-1[54_3]
2-2	8-11	and	abstract[3]	new[3]	_	_
2-3	12-20	Vascular	abstract[3]|abstract|abstract[5]	new[3]|new|new[5]	coref|coref|coref|coref	4-12[16_5]|20-5|4-12[16_5]|20-5
2-4	21-29	Diseases	abstract[3]|abstract[5]	new[3]|new[5]	_	_

#Text=In vascular pathology , hypoxia is typically the consequence of altered , destroyed or absent blood vessels leading to tissue ischemia .
3-1	30-32	In	_	_	_	_
3-2	33-41	vascular	abstract[6]	new[6]	_	_
3-3	42-51	pathology	abstract[6]	new[6]	_	_
3-4	52-53	,	_	_	_	_
3-5	54-61	hypoxia	abstract	new	coref	3-7[8_0]
3-6	62-64	is	_	_	_	_
3-7	65-74	typically	abstract[8]	giv[8]	coref	5-7[0_8]
3-8	75-78	the	abstract[8]	giv[8]	_	_
3-9	79-90	consequence	abstract[8]	giv[8]	_	_
3-10	91-93	of	abstract[8]	giv[8]	_	_
3-11	94-101	altered	abstract[8]	giv[8]	_	_
3-12	102-103	,	abstract[8]	giv[8]	_	_
3-13	104-113	destroyed	abstract[8]	giv[8]	_	_
3-14	114-116	or	abstract[8]	giv[8]	_	_
3-15	117-123	absent	abstract[8]	giv[8]	_	_
3-16	124-129	blood	abstract[8]|substance|object[10]	giv[8]|new|new[10]	coref|coref	22-23|22-23
3-17	130-137	vessels	abstract[8]|object[10]	giv[8]|new[10]	_	_
3-18	138-145	leading	_	_	_	_
3-19	146-148	to	_	_	_	_
3-20	149-155	tissue	object|abstract[12]	new|new[12]	coref|coref|coref|coref	5-2|5-2[29_12]|5-2|5-2[29_12]
3-21	156-164	ischemia	abstract[12]	new[12]	_	_
3-22	165-166	.	_	_	_	_

#Text=The mechanisms of the HIF response have therefore been studied in ischemic vascular diseases , such as myocardial infarction ( consequence of obstruction of coronary arteries ) or peripheral vascular disease ( PAD , consequence of obstruction of arteries going to the limbs ) .
4-1	167-170	The	abstract[13]	new[13]	_	_
4-2	171-181	mechanisms	abstract[13]	new[13]	_	_
4-3	182-184	of	abstract[13]	new[13]	_	_
4-4	185-188	the	abstract[13]|abstract[15]	new[13]|new[15]	coref	6-19[45_15]
4-5	189-192	HIF	abstract[13]|abstract|abstract[15]	new[13]|giv|new[15]	coref	6-7
4-6	193-201	response	abstract[13]|abstract[15]	new[13]|new[15]	_	_
4-7	202-206	have	_	_	_	_
4-8	207-216	therefore	_	_	_	_
4-9	217-221	been	_	_	_	_
4-10	222-229	studied	_	_	_	_
4-11	230-232	in	_	_	_	_
4-12	233-241	ischemic	abstract[16]	giv[16]	coref	5-21[36_16]
4-13	242-250	vascular	abstract[16]	giv[16]	_	_
4-14	251-259	diseases	abstract[16]	giv[16]	_	_
4-15	260-261	,	abstract[16]	giv[16]	_	_
4-16	262-266	such	abstract[16]	giv[16]	_	_
4-17	267-269	as	abstract[16]	giv[16]	_	_
4-18	270-280	myocardial	abstract[16]|event[17]	giv[16]|new[17]	_	_
4-19	281-291	infarction	abstract[16]|event[17]	giv[16]|new[17]	_	_
4-20	292-293	(	_	_	_	_
4-21	294-305	consequence	abstract[18]	new[18]	_	_
4-22	306-308	of	abstract[18]	new[18]	_	_
4-23	309-320	obstruction	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-24	321-323	of	abstract[18]|abstract[19]	new[18]|new[19]	_	_
4-25	324-332	coronary	abstract[18]|abstract[19]|abstract|object[21]	new[18]|new[19]|new|new[21]	coref|coref	4-39[0_21]|4-39[0_21]
4-26	333-341	arteries	abstract[18]|abstract[19]|object[21]	new[18]|new[19]|new[21]	_	_
4-27	342-343	)	_	_	_	_
4-28	344-346	or	_	_	_	_
4-29	347-357	peripheral	abstract[22]	new[22]	coref	12-27[83_22]
4-30	358-366	vascular	abstract[22]	new[22]	_	_
4-31	367-374	disease	abstract[22]	new[22]	_	_
4-32	375-376	(	_	_	_	_
4-33	377-380	PAD	abstract	new	_	_
4-34	381-382	,	_	_	_	_
4-35	383-394	consequence	abstract[24]	new[24]	_	_
4-36	395-397	of	abstract[24]	new[24]	_	_
4-37	398-409	obstruction	abstract[24]|object[25]	new[24]|new[25]	_	_
4-38	410-412	of	abstract[24]|object[25]	new[24]|new[25]	_	_
4-39	413-421	arteries	abstract[24]|object[25]|object	new[24]|new[25]|giv	coref	15-9[112_0]
4-40	422-427	going	_	_	_	_
4-41	428-430	to	_	_	_	_
4-42	431-434	the	object[27]	new[27]	_	_
4-43	435-440	limbs	object[27]	new[27]	_	_
4-44	441-442	)	_	_	_	_
4-45	443-444	.	_	_	_	_

#Text=Besides tissue ischemia , mechanisms of hypoxia and ischemia can occur within the vascular wall itself , with implications for diseases such as atherosclerosis , arterial aneurysm , chronic venous insufficiency and thromboembolism .
5-1	445-452	Besides	_	_	_	_
5-2	453-459	tissue	object|abstract[29]	giv|giv[29]	coref|coref|coref|coref	5-9[0_29]|15-7|5-9[0_29]|15-7
5-3	460-468	ischemia	abstract[29]	giv[29]	_	_
5-4	469-470	,	_	_	_	_
5-5	471-481	mechanisms	abstract[30]	new[30]	_	_
5-6	482-484	of	abstract[30]	new[30]	_	_
5-7	485-492	hypoxia	abstract[30]|abstract	new[30]|giv	coref	12-1
5-8	493-496	and	abstract[30]	new[30]	_	_
5-9	497-505	ischemia	abstract[30]|abstract	new[30]|giv	ana	5-16
5-10	506-509	can	_	_	_	_
5-11	510-515	occur	_	_	_	_
5-12	516-522	within	_	_	_	_
5-13	523-526	the	place[33]	new[33]	coref	6-22[46_33]
5-14	527-535	vascular	place[33]	new[33]	_	_
5-15	536-540	wall	place[33]	new[33]	_	_
5-16	541-547	itself	place[33]|abstract	new[33]|giv	_	_
5-17	548-549	,	_	_	_	_
5-18	550-554	with	_	_	_	_
5-19	555-567	implications	abstract[35]	new[35]	_	_
5-20	568-571	for	abstract[35]	new[35]	_	_
5-21	572-580	diseases	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-22	581-585	such	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-23	586-588	as	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-24	589-604	atherosclerosis	abstract[35]|abstract[36]|abstract	new[35]|giv[36]|new	coref	8-3
5-25	605-606	,	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-26	607-615	arterial	abstract[35]|abstract[36]|abstract[38]	new[35]|giv[36]|new[38]	_	_
5-27	616-624	aneurysm	abstract[35]|abstract[36]|abstract[38]	new[35]|giv[36]|new[38]	_	_
5-28	625-626	,	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-29	627-634	chronic	abstract[35]|abstract[36]|abstract[40]	new[35]|giv[36]|new[40]	_	_
5-30	635-641	venous	abstract[35]|abstract[36]|person|abstract[40]	new[35]|giv[36]|new|new[40]	coref	23-1[156_0]
5-31	642-655	insufficiency	abstract[35]|abstract[36]|abstract[40]	new[35]|giv[36]|new[40]	_	_
5-32	656-659	and	abstract[35]|abstract[36]	new[35]|giv[36]	_	_
5-33	660-675	thromboembolism	abstract[35]|abstract[36]|abstract	new[35]|giv[36]|new	_	_
5-34	676-677	.	_	_	_	_

#Text=There is growing evidence that the HIF pathway is implicated — for better or for worse — in the response of the vascular wall to inadequate oxygenation and/or increased cellular oxygen , a demand secondary to various stresses or injuries .
6-1	678-683	There	_	_	_	_
6-2	684-686	is	_	_	_	_
6-3	687-694	growing	_	_	_	_
6-4	695-703	evidence	abstract[42]	new[42]	_	_
6-5	704-708	that	abstract[42]	new[42]	_	_
6-6	709-712	the	abstract[42]|place[44]	new[42]|new[44]	coref	21-4[144_44]
6-7	713-716	HIF	abstract[42]|abstract|place[44]	new[42]|giv|new[44]	coref	8-1
6-8	717-724	pathway	abstract[42]|place[44]	new[42]|new[44]	_	_
6-9	725-727	is	abstract[42]	new[42]	_	_
6-10	728-738	implicated	abstract[42]	new[42]	_	_
6-11	739-740	—	_	_	_	_
6-12	741-744	for	_	_	_	_
6-13	745-751	better	_	_	_	_
6-14	752-754	or	_	_	_	_
6-15	755-758	for	_	_	_	_
6-16	759-764	worse	_	_	_	_
6-17	765-766	—	_	_	_	_
6-18	767-769	in	_	_	_	_
6-19	770-773	the	abstract[45]	giv[45]	_	_
6-20	774-782	response	abstract[45]	giv[45]	_	_
6-21	783-785	of	abstract[45]	giv[45]	_	_
6-22	786-789	the	abstract[45]|place[46]	giv[45]|giv[46]	coref	9-14[60_46]
6-23	790-798	vascular	abstract[45]|place[46]	giv[45]|giv[46]	_	_
6-24	799-803	wall	abstract[45]|place[46]	giv[45]|giv[46]	_	_
6-25	804-806	to	abstract[45]|place[46]	giv[45]|giv[46]	_	_
6-26	807-817	inadequate	abstract[45]|place[46]|abstract[47]	giv[45]|giv[46]|new[47]	_	_
6-27	818-829	oxygenation	abstract[45]|place[46]|abstract[47]	giv[45]|giv[46]|new[47]	_	_
6-28	830-836	and/or	abstract[45]|place[46]	giv[45]|giv[46]	_	_
6-29	837-846	increased	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	coref	12-8[0_48]
6-30	847-855	cellular	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	_	_
6-31	856-862	oxygen	abstract[45]|place[46]|substance[48]	giv[45]|giv[46]|new[48]	_	_
6-32	863-864	,	_	_	_	_
6-33	865-866	a	abstract[49]	new[49]	coref	12-6[78_49]
6-34	867-873	demand	abstract[49]	new[49]	_	_
6-35	874-883	secondary	abstract[49]	new[49]	_	_
6-36	884-886	to	_	_	_	_
6-37	887-894	various	abstract[50]	new[50]	_	_
6-38	895-903	stresses	abstract[50]	new[50]	_	_
6-39	904-906	or	_	_	_	_
6-40	907-915	injuries	event	new	_	_
6-41	916-917	.	_	_	_	_

#Text=6.1 .
7-1	918-921	6.1	abstract	new	_	_
7-2	922-923	.	_	_	_	_

#Text=HIF and Atherosclerosis
8-1	924-927	HIF	abstract|abstract[54]	giv|giv[54]	coref|coref|coref|coref	18-10|20-1[138_54]|18-10|20-1[138_54]
8-2	928-931	and	abstract[54]	giv[54]	_	_
8-3	932-947	Atherosclerosis	abstract[54]|abstract	giv[54]|giv	coref	9-1

#Text=Atherosclerosis is a condition in which fatty deposits ( plaques ) develop in the arterial wall , leading to stenosis and ultimately to thrombosis of the vessel .
9-1	948-963	Atherosclerosis	abstract	giv	coref	9-3[57_0]
9-2	964-966	is	_	_	_	_
9-3	967-968	a	abstract[57]	giv[57]	_	_
9-4	969-978	condition	abstract[57]	giv[57]	_	_
9-5	979-981	in	_	_	_	_
9-6	982-987	which	_	_	_	_
9-7	988-993	fatty	substance[58]	new[58]	_	_
9-8	994-1002	deposits	substance[58]	new[58]	_	_
9-9	1003-1004	(	_	_	_	_
9-10	1005-1012	plaques	object	new	coref	10-1[64_0]
9-11	1013-1014	)	_	_	_	_
9-12	1015-1022	develop	abstract	new	coref|none	21-8[145_0]|9-12[0_145]
9-13	1023-1025	in	_	_	_	_
9-14	1026-1029	the	place[60]	giv[60]	coref	11-12[0_60]
9-15	1030-1038	arterial	place[60]	giv[60]	_	_
9-16	1039-1043	wall	place[60]	giv[60]	_	_
9-17	1044-1045	,	_	_	_	_
9-18	1046-1053	leading	_	_	_	_
9-19	1054-1056	to	_	_	_	_
9-20	1057-1065	stenosis	event	new	_	_
9-21	1066-1069	and	_	_	_	_
9-22	1070-1080	ultimately	event[62]	new[62]	_	_
9-23	1081-1083	to	event[62]	new[62]	_	_
9-24	1084-1094	thrombosis	event[62]	new[62]	_	_
9-25	1095-1097	of	event[62]	new[62]	_	_
9-26	1098-1101	the	event[62]|object[63]	new[62]|new[63]	coref	25-13[0_63]
9-27	1102-1108	vessel	event[62]|object[63]	new[62]|new[63]	_	_
9-28	1109-1110	.	_	_	_	_

#Text=Atherosclerotic plaques are mainly composed of cholesterol , other lipids , calcium , fibrin and inflammatory cells .
10-1	1111-1126	Atherosclerotic	object[64]	giv[64]	coref	11-5[73_64]
10-2	1127-1134	plaques	object[64]	giv[64]	_	_
10-3	1135-1138	are	_	_	_	_
10-4	1139-1145	mainly	_	_	_	_
10-5	1146-1154	composed	_	_	_	_
10-6	1155-1157	of	_	_	_	_
10-7	1158-1169	cholesterol	substance	new	_	_
10-8	1170-1171	,	_	_	_	_
10-9	1172-1177	other	substance[66]	new[66]	_	_
10-10	1178-1184	lipids	substance[66]	new[66]	_	_
10-11	1185-1186	,	_	_	_	_
10-12	1187-1194	calcium	substance	new	_	_
10-13	1195-1196	,	_	_	_	_
10-14	1197-1203	fibrin	substance	new	_	_
10-15	1204-1207	and	_	_	_	_
10-16	1208-1220	inflammatory	object[69]	new[69]	coref	12-11[79_69]
10-17	1221-1226	cells	object[69]	new[69]	_	_
10-18	1227-1228	.	_	_	_	_

#Text=Oxygen diffusion through space-occupying atherosclerotic plaques could be limited due to wall thickening .
11-1	1229-1235	Oxygen	person|abstract[71]	new|new[71]	_	_
11-2	1236-1245	diffusion	abstract[71]	new[71]	_	_
11-3	1246-1253	through	_	_	_	_
11-4	1254-1269	space-occupying	_	_	_	_
11-5	1270-1285	atherosclerotic	substance|object[73]	new|giv[73]	coref|coref|coref|coref	13-12|13-12[89_73]|13-12|13-12[89_73]
11-6	1286-1293	plaques	object[73]	giv[73]	_	_
11-7	1294-1299	could	_	_	_	_
11-8	1300-1302	be	_	_	_	_
11-9	1303-1310	limited	_	_	_	_
11-10	1311-1314	due	_	_	_	_
11-11	1315-1317	to	_	_	_	_
11-12	1318-1322	wall	place|abstract[75]	giv|new[75]	coref|coref	25-12[178_0]|25-12[178_0]
11-13	1323-1333	thickening	abstract[75]	new[75]	_	_
11-14	1334-1335	.	_	_	_	_

#Text=Hypoxia could also originate from the high oxygen demand of metabolically active inflammatory cells , such as macrophage foam cells that play a pivotal role in this disease .
12-1	1336-1343	Hypoxia	abstract	giv	coref	13-22
12-2	1344-1349	could	_	_	_	_
12-3	1350-1354	also	_	_	_	_
12-4	1355-1364	originate	_	_	_	_
12-5	1365-1369	from	_	_	_	_
12-6	1370-1373	the	abstract[78]	giv[78]	_	_
12-7	1374-1378	high	abstract[78]	giv[78]	_	_
12-8	1379-1385	oxygen	substance|abstract[78]	giv|giv[78]	coref	13-35
12-9	1386-1392	demand	abstract[78]	giv[78]	_	_
12-10	1393-1395	of	abstract[78]	giv[78]	_	_
12-11	1396-1409	metabolically	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-12	1410-1416	active	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-13	1417-1429	inflammatory	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-14	1430-1435	cells	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-15	1436-1437	,	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-16	1438-1442	such	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-17	1443-1445	as	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-18	1446-1456	macrophage	abstract[78]|object[79]|place	giv[78]|giv[79]|new	_	_
12-19	1457-1461	foam	abstract[78]|object[79]|substance	giv[78]|giv[79]|new	_	_
12-20	1462-1467	cells	abstract[78]|object[79]	giv[78]|giv[79]	_	_
12-21	1468-1472	that	_	_	_	_
12-22	1473-1477	play	_	_	_	_
12-23	1478-1479	a	abstract[82]	new[82]	coref	21-1[142_82]
12-24	1480-1487	pivotal	abstract[82]	new[82]	_	_
12-25	1488-1492	role	abstract[82]	new[82]	_	_
12-26	1493-1495	in	abstract[82]	new[82]	_	_
12-27	1496-1500	this	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
12-28	1501-1508	disease	abstract[82]|abstract[83]	new[82]|giv[83]	_	_
12-29	1509-1510	.	_	_	_	_

#Text=Detection of HIF-1α and activation of its target genes occurs in atherosclerotic plaques . During atherogenesis ( plaque build-up ) , hypoxia increases angiogenesis , releases pro-inflammatory mediators , activates MMPs , forms reactive oxygen species , and oxidizes low-density lipoprotein .
13-1	1511-1520	Detection	abstract[84]	new[84]	_	_
13-2	1521-1523	of	abstract[84]	new[84]	_	_
13-3	1524-1530	HIF-1α	abstract[84]|abstract	new[84]|new	coref	15-2
13-4	1531-1534	and	abstract[84]	new[84]	_	_
13-5	1535-1545	activation	abstract[84]|event[86]	new[84]|new[86]	_	_
13-6	1546-1548	of	abstract[84]|event[86]	new[84]|new[86]	_	_
13-7	1549-1552	its	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	coref	16-1[117_87]
13-8	1553-1559	target	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
13-9	1560-1565	genes	abstract[84]|event[86]|abstract[87]	new[84]|new[86]|new[87]	_	_
13-10	1566-1572	occurs	_	_	_	_
13-11	1573-1575	in	_	_	_	_
13-12	1576-1591	atherosclerotic	substance|object[89]	giv|giv[89]	coref|coref|coref|coref	14-4|14-4[103_89]|14-4|14-4[103_89]
13-13	1592-1599	plaques	object[89]	giv[89]	_	_
13-14	1600-1601	.	_	_	_	_
13-15	1602-1608	During	_	_	_	_
13-16	1609-1622	atherogenesis	event	new	appos	13-18[92_0]
13-17	1623-1624	(	_	_	_	_
13-18	1625-1631	plaque	object|event[92]	new|giv[92]	coref|coref	14-9|14-9
13-19	1632-1640	build-up	event[92]	giv[92]	_	_
13-20	1641-1642	)	_	_	_	_
13-21	1643-1644	,	_	_	_	_
13-22	1645-1652	hypoxia	event	giv	coref	18-4
13-23	1653-1662	increases	_	_	_	_
13-24	1663-1675	angiogenesis	abstract	new	_	_
13-25	1676-1677	,	_	_	_	_
13-26	1678-1686	releases	event|person[96]	new|new[96]	_	_
13-27	1687-1703	pro-inflammatory	person[96]	new[96]	_	_
13-28	1704-1713	mediators	person[96]	new[96]	_	_
13-29	1714-1715	,	_	_	_	_
13-30	1716-1725	activates	_	_	_	_
13-31	1726-1730	MMPs	object	new	_	_
13-32	1731-1732	,	_	_	_	_
13-33	1733-1738	forms	_	_	_	_
13-34	1739-1747	reactive	abstract[99]	new[99]	_	_
13-35	1748-1754	oxygen	substance|abstract[99]	giv|new[99]	coref	24-16
13-36	1755-1762	species	abstract[99]	new[99]	_	_
13-37	1763-1764	,	_	_	_	_
13-38	1765-1768	and	_	_	_	_
13-39	1769-1777	oxidizes	_	_	_	_
13-40	1778-1789	low-density	substance[100]	new[100]	_	_
13-41	1790-1801	lipoprotein	substance[100]	new[100]	_	_
13-42	1802-1803	.	_	_	_	_

#Text=Necrotic cores within atherosclerotic plaques can lead to plaque instability and thromboembolic complications .
14-1	1804-1812	Necrotic	place[101]	new[101]	coref	15-18[115_101]
14-2	1813-1818	cores	place[101]	new[101]	_	_
14-3	1819-1825	within	place[101]	new[101]	_	_
14-4	1826-1841	atherosclerotic	place[101]|substance|object[103]	new[101]|giv|giv[103]	coref|coref|coref|coref	15-9|18-16[130_103]|15-9|18-16[130_103]
14-5	1842-1849	plaques	place[101]|object[103]	new[101]|giv[103]	_	_
14-6	1850-1853	can	_	_	_	_
14-7	1854-1858	lead	_	_	_	_
14-8	1859-1861	to	_	_	_	_
14-9	1862-1868	plaque	object|abstract[105]	giv|new[105]	coref|coref|coref|coref	16-17|16-17[121_105]|16-17|16-17[121_105]
14-10	1869-1880	instability	abstract[105]	new[105]	_	_
14-11	1881-1884	and	_	_	_	_
14-12	1885-1899	thromboembolic	person|event[107]	new|new[107]	_	_
14-13	1900-1913	complications	event[107]	new[107]	_	_
14-14	1914-1915	.	_	_	_	_

#Text=The HIF-1α protein is found in tissue surrounding atherosclerotic arteries , inflammatory macrophages and arterial SMCs around these necrotic cores .
15-1	1916-1919	The	substance[109]	new[109]	_	_
15-2	1920-1926	HIF-1α	object|substance[109]	giv|new[109]	coref	26-11
15-3	1927-1934	protein	substance[109]	new[109]	_	_
15-4	1935-1937	is	_	_	_	_
15-5	1938-1943	found	_	_	_	_
15-6	1944-1946	in	_	_	_	_
15-7	1947-1953	tissue	object	giv	_	_
15-8	1954-1965	surrounding	_	_	_	_
15-9	1966-1981	atherosclerotic	abstract|object[112]	giv|giv[112]	coref|coref	22-2|22-2
15-10	1982-1990	arteries	object[112]	giv[112]	_	_
15-11	1991-1992	,	object[112]	giv[112]	_	_
15-12	1993-2005	inflammatory	object[112]|object[113]	giv[112]|new[113]	coref	17-9[125_113]
15-13	2006-2017	macrophages	object[112]|object[113]	giv[112]|new[113]	_	_
15-14	2018-2021	and	object[112]	giv[112]	_	_
15-15	2022-2030	arterial	object[112]|place[114]	giv[112]|new[114]	_	_
15-16	2031-2035	SMCs	object[112]|place[114]	giv[112]|new[114]	_	_
15-17	2036-2042	around	object[112]|place[114]	giv[112]|new[114]	_	_
15-18	2043-2048	these	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
15-19	2049-2057	necrotic	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
15-20	2058-2063	cores	object[112]|place[114]|place[115]	giv[112]|new[114]|giv[115]	_	_
15-21	2064-2065	.	_	_	_	_

#Text=Proangiogenic HIF-target genes , such as VEGF-A , are responsible for intra-plaque neoangiogenesis , contributing to plaque instability .
16-1	2066-2079	Proangiogenic	abstract[117]	giv[117]	_	_
16-2	2080-2090	HIF-target	abstract|abstract[117]	new|giv[117]	_	_
16-3	2091-2096	genes	abstract[117]	giv[117]	_	_
16-4	2097-2098	,	abstract[117]	giv[117]	_	_
16-5	2099-2103	such	abstract[117]	giv[117]	_	_
16-6	2104-2106	as	abstract[117]	giv[117]	_	_
16-7	2107-2113	VEGF-A	abstract[117]|substance	giv[117]|new	_	_
16-8	2114-2115	,	_	_	_	_
16-9	2116-2119	are	_	_	_	_
16-10	2120-2131	responsible	_	_	_	_
16-11	2132-2135	for	_	_	_	_
16-12	2136-2148	intra-plaque	abstract[119]	new[119]	_	_
16-13	2149-2164	neoangiogenesis	abstract[119]	new[119]	_	_
16-14	2165-2166	,	_	_	_	_
16-15	2167-2179	contributing	_	_	_	_
16-16	2180-2182	to	_	_	_	_
16-17	2183-2189	plaque	object|abstract[121]	giv|giv[121]	coref|coref	18-18|18-18
16-18	2190-2201	instability	abstract[121]	giv[121]	_	_
16-19	2202-2203	.	_	_	_	_

#Text=HIF-1 activity also alters the lipid metabolism of macrophages and vascular SMC .
17-1	2204-2209	HIF-1	abstract[122]	new[122]	_	_
17-2	2210-2218	activity	abstract[122]	new[122]	_	_
17-3	2219-2223	also	_	_	_	_
17-4	2224-2230	alters	_	_	_	_
17-5	2231-2234	the	abstract[124]	new[124]	coref	33-24[267_124]
17-6	2235-2240	lipid	object|abstract[124]	new|new[124]	_	_
17-7	2241-2251	metabolism	abstract[124]	new[124]	_	_
17-8	2252-2254	of	abstract[124]	new[124]	_	_
17-9	2255-2266	macrophages	abstract[124]|object[125]	new[124]|giv[125]	coref	18-18[132_125]
17-10	2267-2270	and	abstract[124]|object[125]	new[124]|giv[125]	_	_
17-11	2271-2279	vascular	abstract[124]|object[125]|object[126]	new[124]|giv[125]|new[126]	_	_
17-12	2280-2283	SMC	abstract[124]|object[125]|object[126]	new[124]|giv[125]|new[126]	_	_
17-13	2284-2285	.	_	_	_	_

#Text=Finally , besides hypoxia , several non-hypoxic stimuli of HIF have also been found in plaques and plaque macrophages , such as inflammation , ROS , vasoactive and thrombotic factors .
18-1	2286-2293	Finally	_	_	_	_
18-2	2294-2295	,	_	_	_	_
18-3	2296-2303	besides	_	_	_	_
18-4	2304-2311	hypoxia	abstract	giv	coref	25-9[176_0]
18-5	2312-2313	,	_	_	_	_
18-6	2314-2321	several	abstract[128]	new[128]	_	_
18-7	2322-2333	non-hypoxic	abstract[128]	new[128]	_	_
18-8	2334-2341	stimuli	abstract[128]	new[128]	_	_
18-9	2342-2344	of	abstract[128]	new[128]	_	_
18-10	2345-2348	HIF	abstract[128]|abstract	new[128]|giv	coref	20-1
18-11	2349-2353	have	_	_	_	_
18-12	2354-2358	also	_	_	_	_
18-13	2359-2363	been	_	_	_	_
18-14	2364-2369	found	_	_	_	_
18-15	2370-2372	in	_	_	_	_
18-16	2373-2380	plaques	object[130]	giv[130]	_	_
18-17	2381-2384	and	object[130]	giv[130]	_	_
18-18	2385-2391	plaque	object[130]|object|object[132]	giv[130]|giv|giv[132]	_	_
18-19	2392-2403	macrophages	object[130]|object[132]	giv[130]|giv[132]	_	_
18-20	2404-2405	,	object[130]|object[132]	giv[130]|giv[132]	_	_
18-21	2406-2410	such	object[130]|object[132]	giv[130]|giv[132]	_	_
18-22	2411-2413	as	object[130]|object[132]	giv[130]|giv[132]	_	_
18-23	2414-2426	inflammation	object[130]|object[132]|abstract	giv[130]|giv[132]|new	_	_
18-24	2427-2428	,	object[130]|object[132]	giv[130]|giv[132]	_	_
18-25	2429-2432	ROS	object[130]|object[132]|abstract	giv[130]|giv[132]|new	coref	33-16
18-26	2433-2434	,	object[130]|object[132]	giv[130]|giv[132]	_	_
18-27	2435-2445	vasoactive	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
18-28	2446-2449	and	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
18-29	2450-2460	thrombotic	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
18-30	2461-2468	factors	object[130]|object[132]|abstract[135]	giv[130]|giv[132]|new[135]	_	_
18-31	2469-2470	.	_	_	_	_

#Text=6.2 .
19-1	2471-2474	6.2	abstract	new	_	_
19-2	2475-2476	.	_	_	_	_

#Text=HIF and NH in Vascular Grafts
20-1	2477-2480	HIF	abstract|abstract[138]	giv|giv[138]	coref|coref	21-5|21-5
20-2	2481-2484	and	abstract[138]	giv[138]	_	_
20-3	2485-2487	NH	abstract[138]|substance[139]	giv[138]|new[139]	coref	21-11[0_139]
20-4	2488-2490	in	abstract[138]|substance[139]	giv[138]|new[139]	_	_
20-5	2491-2499	Vascular	abstract[138]|substance[139]|abstract|object[141]	giv[138]|new[139]|giv|new[141]	coref|coref	23-6[158_141]|23-6[158_141]
20-6	2500-2506	Grafts	abstract[138]|substance[139]|object[141]	giv[138]|new[139]|new[141]	_	_

#Text=The role of the HIF pathway in the development of NH has also been studied .
21-1	2507-2510	The	abstract[142]	giv[142]	_	_
21-2	2511-2515	role	abstract[142]	giv[142]	_	_
21-3	2516-2518	of	abstract[142]	giv[142]	_	_
21-4	2519-2522	the	abstract[142]|place[144]	giv[142]|giv[144]	coref	27-6[202_144]
21-5	2523-2526	HIF	abstract[142]|abstract|place[144]	giv[142]|giv|giv[144]	coref	27-7
21-6	2527-2534	pathway	abstract[142]|place[144]	giv[142]|giv[144]	_	_
21-7	2535-2537	in	abstract[142]|place[144]	giv[142]|giv[144]	_	_
21-8	2538-2541	the	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
21-9	2542-2553	development	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
21-10	2554-2556	of	abstract[142]|place[144]|abstract[145]	giv[142]|giv[144]|new[145]	_	_
21-11	2557-2559	NH	abstract[142]|place[144]|abstract[145]|substance	giv[142]|giv[144]|new[145]|giv	coref	23-11
21-12	2560-2563	has	_	_	_	_
21-13	2564-2568	also	_	_	_	_
21-14	2569-2573	been	_	_	_	_
21-15	2574-2581	studied	_	_	_	_
21-16	2582-2583	.	_	_	_	_

#Text=When atherosclerotic lesions occupy a long segment of the artery , surgeons frequently use a graft to bypass the lesion and provide blood to distal tissues .
22-1	2584-2588	When	_	_	_	_
22-2	2589-2604	atherosclerotic	object|object[148]	giv|new[148]	_	_
22-3	2605-2612	lesions	object[148]	new[148]	_	_
22-4	2613-2619	occupy	_	_	_	_
22-5	2620-2621	a	place[149]	new[149]	_	_
22-6	2622-2626	long	place[149]	new[149]	_	_
22-7	2627-2634	segment	place[149]	new[149]	_	_
22-8	2635-2637	of	place[149]	new[149]	_	_
22-9	2638-2641	the	place[149]|place[150]	new[149]|new[150]	_	_
22-10	2642-2648	artery	place[149]|place[150]	new[149]|new[150]	_	_
22-11	2649-2650	,	_	_	_	_
22-12	2651-2659	surgeons	person	new	_	_
22-13	2660-2670	frequently	_	_	_	_
22-14	2671-2674	use	_	_	_	_
22-15	2675-2676	a	object[152]	new[152]	coref	28-4[213_152]
22-16	2677-2682	graft	object[152]	new[152]	_	_
22-17	2683-2685	to	_	_	_	_
22-18	2686-2692	bypass	_	_	_	_
22-19	2693-2696	the	object[153]	new[153]	_	_
22-20	2697-2703	lesion	object[153]	new[153]	_	_
22-21	2704-2707	and	_	_	_	_
22-22	2708-2715	provide	_	_	_	_
22-23	2716-2721	blood	substance	giv	_	_
22-24	2722-2724	to	_	_	_	_
22-25	2725-2731	distal	place[155]	new[155]	_	_
22-26	2732-2739	tissues	place[155]	new[155]	_	_
22-27	2740-2741	.	_	_	_	_

#Text=Either venous or prosthetic , these grafts are prone to NH .
23-1	2742-2748	Either	person[156]	giv[156]	coref	26-29[0_156]
23-2	2749-2755	venous	person[156]	giv[156]	_	_
23-3	2756-2758	or	_	_	_	_
23-4	2759-2769	prosthetic	object	new	_	_
23-5	2770-2771	,	_	_	_	_
23-6	2772-2777	these	object[158]	giv[158]	coref	24-2[161_158]
23-7	2778-2784	grafts	object[158]	giv[158]	_	_
23-8	2785-2788	are	_	_	_	_
23-9	2789-2794	prone	_	_	_	_
23-10	2795-2797	to	_	_	_	_
23-11	2798-2800	NH	abstract	giv	coref	24-22
23-12	2801-2802	.	_	_	_	_

#Text=Although vein grafts and prosthetic grafts are not identical , because of different hemodynamics and oxygen tension , the characteristics of NH in vein grafts are similar to those of NH that form in AVFs .
24-1	2803-2811	Although	_	_	_	_
24-2	2812-2816	vein	plant|object[161]	new|giv[161]	coref|coref|coref|coref	24-24|24-24[169_161]|24-24|24-24[169_161]
24-3	2817-2823	grafts	object[161]	giv[161]	_	_
24-4	2824-2827	and	object[161]	giv[161]	_	_
24-5	2828-2838	prosthetic	object[161]	giv[161]	_	_
24-6	2839-2845	grafts	object[161]	giv[161]	_	_
24-7	2846-2849	are	_	_	_	_
24-8	2850-2853	not	_	_	_	_
24-9	2854-2863	identical	_	_	_	_
24-10	2864-2865	,	_	_	_	_
24-11	2866-2873	because	_	_	_	_
24-12	2874-2876	of	_	_	_	_
24-13	2877-2886	different	abstract[162]|person[163]	new[162]|new[163]	ana|ana	28-1[0_163]|28-1[0_163]
24-14	2887-2899	hemodynamics	abstract[162]|person[163]	new[162]|new[163]	_	_
24-15	2900-2903	and	person[163]	new[163]	_	_
24-16	2904-2910	oxygen	person[163]|substance|abstract[165]	new[163]|giv|new[165]	ana|coref|ana|coref	24-29[170_165]|33-10|24-29[170_165]|33-10
24-17	2911-2918	tension	person[163]|abstract[165]	new[163]|new[165]	_	_
24-18	2919-2920	,	_	_	_	_
24-19	2921-2924	the	abstract[166]	new[166]	_	_
24-20	2925-2940	characteristics	abstract[166]	new[166]	_	_
24-21	2941-2943	of	abstract[166]	new[166]	_	_
24-22	2944-2946	NH	abstract[166]|substance	new[166]|giv	coref	24-31
24-23	2947-2949	in	abstract[166]	new[166]	_	_
24-24	2950-2954	vein	abstract[166]|plant|object[169]	new[166]|giv|giv[169]	coref|coref|coref|coref	25-7[0_169]|28-5|25-7[0_169]|28-5
24-25	2955-2961	grafts	abstract[166]|object[169]	new[166]|giv[169]	_	_
24-26	2962-2965	are	_	_	_	_
24-27	2966-2973	similar	_	_	_	_
24-28	2974-2976	to	_	_	_	_
24-29	2977-2982	those	abstract[170]	giv[170]	_	_
24-30	2983-2985	of	abstract[170]	giv[170]	_	_
24-31	2986-2988	NH	abstract[170]|substance	giv[170]|giv	coref	26-30
24-32	2989-2993	that	_	_	_	_
24-33	2994-2998	form	_	_	_	_
24-34	2999-3001	in	_	_	_	_
24-35	3002-3006	AVFs	abstract	new	_	_
24-36	3007-3008	.	_	_	_	_

#Text=In studies with animal models , grafts showed increased hypoxia within the vessel wall in regions of neointimal hyperplasia .
25-1	3009-3011	In	_	_	_	_
25-2	3012-3019	studies	abstract[173]	new[173]	coref	32-1[246_173]
25-3	3020-3024	with	abstract[173]	new[173]	_	_
25-4	3025-3031	animal	abstract[173]|abstract[174]	new[173]|new[174]	_	_
25-5	3032-3038	models	abstract[173]|abstract[174]	new[173]|new[174]	_	_
25-6	3039-3040	,	_	_	_	_
25-7	3041-3047	grafts	object	giv	coref	26-20
25-8	3048-3054	showed	_	_	_	_
25-9	3055-3064	increased	abstract[176]	giv[176]	coref	26-26[0_176]
25-10	3065-3072	hypoxia	abstract[176]	giv[176]	_	_
25-11	3073-3079	within	abstract[176]	giv[176]	_	_
25-12	3080-3083	the	abstract[176]|place[178]	giv[176]|giv[178]	coref	32-26[254_178]
25-13	3084-3090	vessel	abstract[176]|object|place[178]	giv[176]|giv|giv[178]	_	_
25-14	3091-3095	wall	abstract[176]|place[178]	giv[176]|giv[178]	_	_
25-15	3096-3098	in	abstract[176]|place[178]	giv[176]|giv[178]	_	_
25-16	3099-3106	regions	abstract[176]|place[178]|place[179]	giv[176]|giv[178]|new[179]	_	_
25-17	3107-3109	of	abstract[176]|place[178]|place[179]	giv[176]|giv[178]|new[179]	_	_
25-18	3110-3120	neointimal	abstract[176]|place[178]|place[179]|person|abstract[181]	giv[176]|giv[178]|new[179]|new|new[181]	coref|coref|coref|coref	26-17|26-17[190_181]|26-17|26-17[190_181]
25-19	3121-3132	hyperplasia	abstract[176]|place[178]|place[179]|abstract[181]	giv[176]|giv[178]|new[179]|new[181]	_	_
25-20	3133-3134	.	_	_	_	_

#Text=A study using a porcine model showed an association of HIF-1α expression with the degree of neointimal hyperplasia in grafts , and suggested that reducing hypoxia might inhibit venous NH formation , possibly by reducing the phenotypic switch of fibroblasts to myofibroblasts .
26-1	3135-3136	A	abstract[182]	new[182]	_	_
26-2	3137-3142	study	abstract[182]	new[182]	_	_
26-3	3143-3148	using	_	_	_	_
26-4	3149-3150	a	abstract[184]	new[184]	_	_
26-5	3151-3158	porcine	substance|abstract[184]	new|new[184]	_	_
26-6	3159-3164	model	abstract[184]	new[184]	_	_
26-7	3165-3171	showed	_	_	_	_
26-8	3172-3174	an	abstract[185]	new[185]	_	_
26-9	3175-3186	association	abstract[185]	new[185]	_	_
26-10	3187-3189	of	abstract[185]	new[185]	_	_
26-11	3190-3196	HIF-1α	abstract[185]|abstract|abstract[187]	new[185]|giv|new[187]	coref|coref|coref|coref	30-15[230_0]|30-18[232_187]|30-15[230_0]|30-18[232_187]
26-12	3197-3207	expression	abstract[185]|abstract[187]	new[185]|new[187]	_	_
26-13	3208-3212	with	abstract[185]|abstract[187]	new[185]|new[187]	_	_
26-14	3213-3216	the	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
26-15	3217-3223	degree	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
26-16	3224-3226	of	abstract[185]|abstract[187]|abstract[188]	new[185]|new[187]|new[188]	_	_
26-17	3227-3237	neointimal	abstract[185]|abstract[187]|abstract[188]|person|abstract[190]	new[185]|new[187]|new[188]|giv|giv[190]	_	_
26-18	3238-3249	hyperplasia	abstract[185]|abstract[187]|abstract[188]|abstract[190]	new[185]|new[187]|new[188]|giv[190]	_	_
26-19	3250-3252	in	abstract[185]|abstract[187]|abstract[188]|abstract[190]	new[185]|new[187]|new[188]|giv[190]	_	_
26-20	3253-3259	grafts	abstract[185]|abstract[187]|abstract[188]|abstract[190]|object	new[185]|new[187]|new[188]|giv[190]|giv	_	_
26-21	3260-3261	,	_	_	_	_
26-22	3262-3265	and	_	_	_	_
26-23	3266-3275	suggested	_	_	_	_
26-24	3276-3280	that	_	_	_	_
26-25	3281-3289	reducing	_	_	_	_
26-26	3290-3297	hypoxia	abstract	giv	coref	32-29
26-27	3298-3303	might	_	_	_	_
26-28	3304-3311	inhibit	_	_	_	_
26-29	3312-3318	venous	person|abstract[195]	giv|new[195]	coref|coref	27-13[204_195]|27-13[204_195]
26-30	3319-3321	NH	object|abstract[195]	giv|new[195]	coref	27-13
26-31	3322-3331	formation	abstract[195]	new[195]	_	_
26-32	3332-3333	,	_	_	_	_
26-33	3334-3342	possibly	_	_	_	_
26-34	3343-3345	by	_	_	_	_
26-35	3346-3354	reducing	_	_	_	_
26-36	3355-3358	the	object[197]	new[197]	_	_
26-37	3359-3369	phenotypic	abstract|object[197]	new|new[197]	_	_
26-38	3370-3376	switch	object[197]	new[197]	_	_
26-39	3377-3379	of	object[197]	new[197]	_	_
26-40	3380-3391	fibroblasts	object[197]|object[198]	new[197]|new[198]	_	_
26-41	3392-3394	to	object[197]|object[198]	new[197]|new[198]	_	_
26-42	3395-3409	myofibroblasts	object[197]|object[198]|object	new[197]|new[198]|new	_	_
26-43	3410-3411	.	_	_	_	_

#Text=Paradoxically , increased activation of the HIF pathway may also protect against NH formation . Nakao et al. studied the role of carbon monoxide , a physiologically important vasodilator that acts via cyclic guanosine monophosphate , in the formation of NH .
27-1	3412-3425	Paradoxically	_	_	_	_
27-2	3426-3427	,	_	_	_	_
27-3	3428-3437	increased	abstract[200]	new[200]	_	_
27-4	3438-3448	activation	abstract[200]	new[200]	_	_
27-5	3449-3451	of	abstract[200]	new[200]	_	_
27-6	3452-3455	the	abstract[200]|place[202]	new[200]|giv[202]	coref	31-33[245_202]
27-7	3456-3459	HIF	abstract[200]|abstract|place[202]	new[200]|giv|giv[202]	coref	31-34
27-8	3460-3467	pathway	abstract[200]|place[202]	new[200]|giv[202]	_	_
27-9	3468-3471	may	_	_	_	_
27-10	3472-3476	also	_	_	_	_
27-11	3477-3484	protect	_	_	_	_
27-12	3485-3492	against	_	_	_	_
27-13	3493-3495	NH	substance|abstract[204]	giv|giv[204]	coref|coref|coref|coref	27-38[209_204]|27-41|27-38[209_204]|27-41
27-14	3496-3505	formation	abstract[204]	giv[204]	_	_
27-15	3506-3507	.	_	_	_	_
27-16	3508-3513	Nakao	person	new	_	_
27-17	3514-3516	et	_	_	_	_
27-18	3517-3520	al.	_	_	_	_
27-19	3521-3528	studied	_	_	_	_
27-20	3529-3532	the	abstract[206]	new[206]	_	_
27-21	3533-3537	role	abstract[206]	new[206]	_	_
27-22	3538-3540	of	abstract[206]	new[206]	_	_
27-23	3541-3547	carbon	abstract[206]|substance[207]	new[206]|new[207]	appos	27-26[208_207]
27-24	3548-3556	monoxide	abstract[206]|substance[207]	new[206]|new[207]	_	_
27-25	3557-3558	,	_	_	_	_
27-26	3559-3560	a	substance[208]	giv[208]	coref	29-11[222_208]
27-27	3561-3576	physiologically	substance[208]	giv[208]	_	_
27-28	3577-3586	important	substance[208]	giv[208]	_	_
27-29	3587-3598	vasodilator	substance[208]	giv[208]	_	_
27-30	3599-3603	that	_	_	_	_
27-31	3604-3608	acts	_	_	_	_
27-32	3609-3612	via	_	_	_	_
27-33	3613-3619	cyclic	_	_	_	_
27-34	3620-3629	guanosine	_	_	_	_
27-35	3630-3643	monophosphate	_	_	_	_
27-36	3644-3645	,	_	_	_	_
27-37	3646-3648	in	_	_	_	_
27-38	3649-3652	the	abstract[209]	giv[209]	coref	30-8[229_209]
27-39	3653-3662	formation	abstract[209]	giv[209]	_	_
27-40	3663-3665	of	abstract[209]	giv[209]	_	_
27-41	3666-3668	NH	abstract[209]|substance	giv[209]|giv	coref	28-13[215_0]
27-42	3669-3670	.	_	_	_	_

#Text=They showed that a vein graft placed immediately after harvest led to less NH than if the graft was rinsed with lactated Ringer for 2 h prior to surgical placement .
28-1	3671-3675	They	person	giv	_	_
28-2	3676-3682	showed	_	_	_	_
28-3	3683-3687	that	_	_	_	_
28-4	3688-3689	a	object[213]	giv[213]	coref	28-17[216_213]
28-5	3690-3694	vein	plant|object[213]	giv|giv[213]	coref	32-14
28-6	3695-3700	graft	object[213]	giv[213]	_	_
28-7	3701-3707	placed	_	_	_	_
28-8	3708-3719	immediately	_	_	_	_
28-9	3720-3725	after	_	_	_	_
28-10	3726-3733	harvest	event	new	_	_
28-11	3734-3737	led	_	_	_	_
28-12	3738-3740	to	_	_	_	_
28-13	3741-3745	less	substance[215]	giv[215]	coref	29-17[0_215]
28-14	3746-3748	NH	substance[215]	giv[215]	_	_
28-15	3749-3753	than	_	_	_	_
28-16	3754-3756	if	_	_	_	_
28-17	3757-3760	the	object[216]	giv[216]	coref	32-15[0_216]
28-18	3761-3766	graft	object[216]	giv[216]	_	_
28-19	3767-3770	was	_	_	_	_
28-20	3771-3777	rinsed	_	_	_	_
28-21	3778-3782	with	_	_	_	_
28-22	3783-3791	lactated	person[217]	new[217]	coref	29-6[0_217]
28-23	3792-3798	Ringer	person[217]	new[217]	_	_
28-24	3799-3802	for	person[217]	new[217]	_	_
28-25	3803-3804	2	person[217]|time[218]	new[217]|new[218]	_	_
28-26	3805-3806	h	person[217]|time[218]	new[217]|new[218]	_	_
28-27	3807-3812	prior	_	_	_	_
28-28	3813-3815	to	_	_	_	_
28-29	3816-3824	surgical	event[219]	new[219]	_	_
28-30	3825-3834	placement	event[219]	new[219]	_	_
28-31	3835-3836	.	_	_	_	_

#Text=However , if the lactated Ringer solution was saturated with carbon monoxide , it significantly inhibited NH compared to the untreated control .
29-1	3837-3844	However	_	_	_	_
29-2	3845-3846	,	_	_	_	_
29-3	3847-3849	if	_	_	_	_
29-4	3850-3853	the	substance[221]	new[221]	_	_
29-5	3854-3862	lactated	substance[221]	new[221]	_	_
29-6	3863-3869	Ringer	person|substance[221]	giv|new[221]	_	_
29-7	3870-3878	solution	substance[221]	new[221]	_	_
29-8	3879-3882	was	_	_	_	_
29-9	3883-3892	saturated	_	_	_	_
29-10	3893-3897	with	_	_	_	_
29-11	3898-3904	carbon	substance[222]	giv[222]	ana	29-14[0_222]
29-12	3905-3913	monoxide	substance[222]	giv[222]	_	_
29-13	3914-3915	,	_	_	_	_
29-14	3916-3918	it	substance	giv	coref	30-4[227_0]
29-15	3919-3932	significantly	_	_	_	_
29-16	3933-3942	inhibited	_	_	_	_
29-17	3943-3945	NH	substance	giv	coref	30-8
29-18	3946-3954	compared	_	_	_	_
29-19	3955-3957	to	_	_	_	_
29-20	3958-3961	the	substance[225]	new[225]	_	_
29-21	3962-3971	untreated	substance[225]	new[225]	_	_
29-22	3972-3979	control	substance[225]	new[225]	_	_
29-23	3980-3981	.	_	_	_	_

#Text=The effects of carbon monoxide in inhibiting NH formation seemed to be associated with increased HIF-1α and VEGF expression a few hours after grafting .
30-1	3982-3985	The	abstract[226]	new[226]	coref	31-25[242_226]
30-2	3986-3993	effects	abstract[226]	new[226]	_	_
30-3	3994-3996	of	abstract[226]	new[226]	_	_
30-4	3997-4003	carbon	abstract[226]|substance[227]	new[226]|giv[227]	coref	33-1[259_227]
30-5	4004-4012	monoxide	abstract[226]|substance[227]	new[226]|giv[227]	_	_
30-6	4013-4015	in	_	_	_	_
30-7	4016-4026	inhibiting	_	_	_	_
30-8	4027-4029	NH	substance|abstract[229]	giv|giv[229]	coref|coref	32-14[250_0]|32-14[250_0]
30-9	4030-4039	formation	abstract[229]	giv[229]	_	_
30-10	4040-4046	seemed	_	_	_	_
30-11	4047-4049	to	_	_	_	_
30-12	4050-4052	be	_	_	_	_
30-13	4053-4063	associated	_	_	_	_
30-14	4064-4068	with	_	_	_	_
30-15	4069-4078	increased	abstract[230]	giv[230]	coref	31-18[0_230]
30-16	4079-4085	HIF-1α	abstract[230]	giv[230]	_	_
30-17	4086-4089	and	_	_	_	_
30-18	4090-4094	VEGF	person|abstract[232]	new|giv[232]	_	_
30-19	4095-4105	expression	abstract[232]	giv[232]	_	_
30-20	4106-4107	a	time[233]	new[233]	_	_
30-21	4108-4111	few	time[233]	new[233]	_	_
30-22	4112-4117	hours	time[233]	new[233]	_	_
30-23	4118-4123	after	_	_	_	_
30-24	4124-4132	grafting	_	_	_	_
30-25	4133-4134	.	_	_	_	_

#Text=This effect , including the induction of VEGF , was reversed by treatment with YC-1 , a HIF-1α inhibitor , supporting the conclusion that these effects were mediated through the activation of the HIF pathway .
31-1	4135-4139	This	abstract[234]	new[234]	_	_
31-2	4140-4146	effect	abstract[234]	new[234]	_	_
31-3	4147-4148	,	abstract[234]	new[234]	_	_
31-4	4149-4158	including	abstract[234]	new[234]	_	_
31-5	4159-4162	the	abstract[234]|event[235]	new[234]|new[235]	_	_
31-6	4163-4172	induction	abstract[234]|event[235]	new[234]|new[235]	_	_
31-7	4173-4175	of	abstract[234]|event[235]	new[234]|new[235]	_	_
31-8	4176-4180	VEGF	abstract[234]|event[235]|substance	new[234]|new[235]|new	_	_
31-9	4181-4182	,	_	_	_	_
31-10	4183-4186	was	_	_	_	_
31-11	4187-4195	reversed	_	_	_	_
31-12	4196-4198	by	_	_	_	_
31-13	4199-4208	treatment	event[237]	new[237]	_	_
31-14	4209-4213	with	event[237]	new[237]	_	_
31-15	4214-4218	YC-1	event[237]|substance	new[237]|new	_	_
31-16	4219-4220	,	_	_	_	_
31-17	4221-4222	a	object[240]	new[240]	_	_
31-18	4223-4229	HIF-1α	abstract|object[240]	giv|new[240]	_	_
31-19	4230-4239	inhibitor	object[240]	new[240]	_	_
31-20	4240-4241	,	_	_	_	_
31-21	4242-4252	supporting	_	_	_	_
31-22	4253-4256	the	abstract[241]	new[241]	_	_
31-23	4257-4267	conclusion	abstract[241]	new[241]	_	_
31-24	4268-4272	that	abstract[241]	new[241]	_	_
31-25	4273-4278	these	abstract[241]|abstract[242]	new[241]|giv[242]	coref	33-6[261_242]
31-26	4279-4286	effects	abstract[241]|abstract[242]	new[241]|giv[242]	_	_
31-27	4287-4291	were	abstract[241]	new[241]	_	_
31-28	4292-4300	mediated	abstract[241]	new[241]	_	_
31-29	4301-4308	through	_	_	_	_
31-30	4309-4312	the	event[243]	new[243]	_	_
31-31	4313-4323	activation	event[243]	new[243]	_	_
31-32	4324-4326	of	event[243]	new[243]	_	_
31-33	4327-4330	the	event[243]|place[245]	new[243]|giv[245]	coref	32-21[253_245]
31-34	4331-4334	HIF	event[243]|abstract|place[245]	new[243]|giv|giv[245]	coref	32-22
31-35	4335-4342	pathway	event[243]|place[245]	new[243]|giv[245]	_	_
31-36	4343-4344	.	_	_	_	_

#Text=These apparently contradictory studies suggest that , at least in the setting of vein graft NH , transient activation of the HIF pathway may protect the wall from hypoxia , whereas chronic activation may maintain the ongoing NH process .
32-1	4345-4350	These	abstract[246]	giv[246]	_	_
32-2	4351-4361	apparently	abstract[246]	giv[246]	_	_
32-3	4362-4375	contradictory	abstract[246]	giv[246]	_	_
32-4	4376-4383	studies	abstract[246]	giv[246]	_	_
32-5	4384-4391	suggest	_	_	_	_
32-6	4392-4396	that	_	_	_	_
32-7	4397-4398	,	_	_	_	_
32-8	4399-4401	at	abstract[247]	new[247]	_	_
32-9	4402-4407	least	abstract[247]	new[247]	_	_
32-10	4408-4410	in	abstract[247]	new[247]	_	_
32-11	4411-4414	the	abstract[247]	new[247]	_	_
32-12	4415-4422	setting	abstract[247]	new[247]	_	_
32-13	4423-4425	of	abstract[247]	new[247]	_	_
32-14	4426-4430	vein	abstract[247]|plant|substance[250]	new[247]|giv|giv[250]	coref|coref	32-38[0_250]|32-38[0_250]
32-15	4431-4436	graft	abstract[247]|object|substance[250]	new[247]|giv|giv[250]	_	_
32-16	4437-4439	NH	abstract[247]|substance[250]	new[247]|giv[250]	_	_
32-17	4440-4441	,	_	_	_	_
32-18	4442-4451	transient	abstract[251]	new[251]	coref	32-32[256_251]
32-19	4452-4462	activation	abstract[251]	new[251]	_	_
32-20	4463-4465	of	abstract[251]	new[251]	_	_
32-21	4466-4469	the	abstract[251]|place[253]	new[251]|giv[253]	_	_
32-22	4470-4473	HIF	abstract[251]|abstract|place[253]	new[251]|giv|giv[253]	_	_
32-23	4474-4481	pathway	abstract[251]|place[253]	new[251]|giv[253]	_	_
32-24	4482-4485	may	_	_	_	_
32-25	4486-4493	protect	_	_	_	_
32-26	4494-4497	the	place[254]	giv[254]	coref	33-26[268_254]
32-27	4498-4502	wall	place[254]	giv[254]	_	_
32-28	4503-4507	from	_	_	_	_
32-29	4508-4515	hypoxia	abstract	giv	_	_
32-30	4516-4517	,	_	_	_	_
32-31	4518-4525	whereas	_	_	_	_
32-32	4526-4533	chronic	event[256]	giv[256]	_	_
32-33	4534-4544	activation	event[256]	giv[256]	_	_
32-34	4545-4548	may	_	_	_	_
32-35	4549-4557	maintain	_	_	_	_
32-36	4558-4561	the	abstract[258]	new[258]	_	_
32-37	4562-4569	ongoing	abstract[258]	new[258]	_	_
32-38	4570-4572	NH	substance|abstract[258]	giv|new[258]	_	_
32-39	4573-4580	process	abstract[258]	new[258]	_	_
32-40	4581-4582	.	_	_	_	_

#Text=Carbon monoxide may also display vasoconstrictor effects depending on oxygen and metabolic homeostasis , including ROS production , highlighting the important role of metabolism in the vascular wall .
33-1	4583-4589	Carbon	substance[259]	giv[259]	_	_
33-2	4590-4598	monoxide	substance[259]	giv[259]	_	_
33-3	4599-4602	may	_	_	_	_
33-4	4603-4607	also	_	_	_	_
33-5	4608-4615	display	_	_	_	_
33-6	4616-4631	vasoconstrictor	abstract|abstract[261]	new|giv[261]	_	_
33-7	4632-4639	effects	abstract[261]	giv[261]	_	_
33-8	4640-4649	depending	_	_	_	_
33-9	4650-4652	on	_	_	_	_
33-10	4653-4659	oxygen	substance	giv	_	_
33-11	4660-4663	and	_	_	_	_
33-12	4664-4673	metabolic	abstract[263]	new[263]	_	_
33-13	4674-4685	homeostasis	abstract[263]	new[263]	_	_
33-14	4686-4687	,	abstract[263]	new[263]	_	_
33-15	4688-4697	including	abstract[263]	new[263]	_	_
33-16	4698-4701	ROS	abstract[263]|substance|abstract[265]	new[263]|giv|new[265]	_	_
33-17	4702-4712	production	abstract[263]|abstract[265]	new[263]|new[265]	_	_
33-18	4713-4714	,	_	_	_	_
33-19	4715-4727	highlighting	_	_	_	_
33-20	4728-4731	the	abstract[266]	new[266]	_	_
33-21	4732-4741	important	abstract[266]	new[266]	_	_
33-22	4742-4746	role	abstract[266]	new[266]	_	_
33-23	4747-4749	of	abstract[266]	new[266]	_	_
33-24	4750-4760	metabolism	abstract[266]|abstract[267]	new[266]|giv[267]	_	_
33-25	4761-4763	in	abstract[266]|abstract[267]	new[266]|giv[267]	_	_
33-26	4764-4767	the	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
33-27	4768-4776	vascular	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
33-28	4777-4781	wall	abstract[266]|abstract[267]|place[268]	new[266]|giv[267]|giv[268]	_	_
33-29	4782-4783	.	_	_	_	_
